Drug intelligence / Profile preview

TNAT-101

Development stage: Preclinical
Lead developer: TNA Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

TNAT-101 is a preclinical-stage small molecule inhibitor developed by TNA Therapeutics. It specifically targets B-cell lymphoma 3 (BCL3), a proto-oncogene and member of the IκB family that acts as a transcriptional co-activator for NF-κB. BCL3 is frequently overexpressed in various solid tumors and is associated with cancer cell survival, metastasis, and resistance to therapy. TNAT-101 is being investigated for the treatment of colorectal cancer (CRC) and triple-negative breast cancer (TNBC), where BCL3 signaling plays a critical role in disease progression.

Targets

BCL3 (B-cell lymphoma 3 protein)

Beyond the preview

Go deeper on TNAT-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TNAT-101.

Explore the full profile